← All trials
NCT04668235
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Jun 30, 2021
- Completion date
- Jun 30, 2021
- First posted
- Dec 16, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 342
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- HRH Pharmaceuticals LimitedLead sponsor
- UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF), BrazilCollaborator
- Galzu InstituteStudy chair
- Galzu InstituteCollaborator
- Santa Casa de Misericordia de SantosCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.